Your browser doesn't support javascript.
loading
Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.
Colletti, Steven L; Frie, Jessica L; Dixon, Elizabeth C; Singh, Suresh B; Choi, Bernard K; Scapin, Giovanna; Fitzgerald, Catherine E; Kumar, Sanjeev; Nichols, Elizabeth A; O'Keefe, Stephen J; O'Neill, Edward A; Porter, Gene; Samuel, Koppara; Schmatz, Dennis M; Schwartz, Cheryl D; Shoop, Wesley L; Thompson, Chris M; Thompson, James E; Wang, Ruixiu; Woods, Andrea; Zaller, Dennis M; Doherty, James B.
Affiliation
  • Colletti SL; Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey 07065, USA. steve_colletti@merck.com
J Med Chem ; 46(3): 349-52, 2003 Jan 30.
Article in En | MEDLINE | ID: mdl-12540232
ABSTRACT
Imidazo[1,2-a]pyridyl N-arylpyridazinones were hybridized from the classic pyridinylimidazoles and the more recent dual hydrogen bond acceptors, resulting in a new structural class of selective p38 MAP kinase inhibitors.
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pyridazines / Mitogen-Activated Protein Kinases / Enzyme Inhibitors Limits: Animals Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2003 Document type: Article Affiliation country: United States
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pyridazines / Mitogen-Activated Protein Kinases / Enzyme Inhibitors Limits: Animals Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2003 Document type: Article Affiliation country: United States